Please use this identifier to cite or link to this item:
|Title:||Optimizing labeling conditions of 213Bi somatostatin analogues for receptor mediated process in preclinical models|
|Authors:||CHAN Ho-Sze; DE BLOIS Erik; KONIJNENBERG M.w.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BREEMAN Wouter; DE JONG Marion|
|Citation:||JOURNAL OF NUCLEAR MEDICINE vol. 55 no. Supplement 1 p. 1179|
|Publisher:||SOC NUCLEAR MEDICINE INC|
|Type:||Articles in periodicals and books|
|Abstract:||The use of alpha emitters as a therapeutic nuclide for cancer therapy becomes more interesting in the field of Nuclear Medicine. 213Bi (t1/2 = 45.6 min) is one of the most widely used alpha emitter. For receptor-mediated processes high specific activity (SA, expressed in MBq per mass ligand) is required, since the uptake is dependent on the amounts of receptors available on the tumor. However due to the radiochemical limitation; e.g. high osmolarity, large reaction volume, etc., applications to in vitro and in vivo for this processes, especially in a mouse model (<0.2 mL at 0.3 osmol in a 25 g mouse) are problematic and need adjustment. Here we present optimized labeling conditions of 213Bi-DOTA-TATE for preclinical applications. Beside optimizing the conditions, the radiochemical purity (RCP) was monitored.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.